Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Sells $608,700.00 in Stock

Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Michael Thomas Henderson sold 15,000 shares of the business’s stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $40.58, for a total transaction of $608,700.00. Following the transaction, the chief executive officer now directly owns 1,302,987 shares in the company, valued at approximately $52,875,212.46. The trade was a 1.14 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Michael Thomas Henderson also recently made the following trade(s):

• On Wednesday, January 8th, Michael Thomas Henderson sold 15,000 shares of Apogee Therapeutics stock. The shares were sold at an average price of $48.85, for a total transaction of $732,750.00.
• On Wednesday, December 4th, Michael Thomas Henderson sold 15,000 shares of Apogee Therapeutics stock. The stock was sold at an average price of $46.58, for a total transaction of $698,700.00.

Apogee Therapeutics Trading Down 4.6 %

Shares of NASDAQ:APGE opened at $39.72 on Monday. Apogee Therapeutics, Inc. has a 12-month low of $33.14 and a 12-month high of $72.29. The stock has a market capitalization of $1.79 billion, a price-to-earnings ratio of -16.41 and a beta of 2.18. The stock has a fifty day simple moving average of $44.25 and a two-hundred day simple moving average of $48.52.

Apogee Therapeutics (NASDAQ:APGE) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.13). As a group, equities research analysts predict that Apogee Therapeutics, Inc. will post -3.09 EPS for the current year.

Institutional Investors Weigh In On Apogee Therapeutics

A number of institutional investors have recently made changes to their positions in the company. Point72 Asset Management L.P. lifted its position in Apogee Therapeutics by 162.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 707,268 shares of the company’s stock valued at $41,545,000 after acquiring an additional 438,036 shares in the last quarter. Waypoint Capital Advisors LLC purchased a new position in shares of Apogee Therapeutics in the third quarter worth $36,835,000. AQR Capital Management LLC bought a new position in shares of Apogee Therapeutics during the second quarter valued at $454,000. Geode Capital Management LLC boosted its position in shares of Apogee Therapeutics by 11.2% during the third quarter. Geode Capital Management LLC now owns 823,839 shares of the company’s stock valued at $48,401,000 after buying an additional 82,978 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in Apogee Therapeutics by 17.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 280,428 shares of the company’s stock worth $16,472,000 after buying an additional 41,686 shares in the last quarter. Hedge funds and other institutional investors own 79.04% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Guggenheim reiterated a “buy” rating on shares of Apogee Therapeutics in a report on Thursday, December 12th. Canaccord Genuity Group started coverage on Apogee Therapeutics in a research note on Monday, November 25th. They issued a “buy” rating and a $89.00 price target on the stock. Wedbush increased their price objective on Apogee Therapeutics from $87.00 to $90.00 and gave the stock an “outperform” rating in a report on Monday, December 2nd. Finally, Canaccord Genuity Group assumed coverage on shares of Apogee Therapeutics in a report on Monday, November 25th. They set a “buy” rating and a $89.00 target price on the stock. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $89.71.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.